United Therapeutics Corporation

University of California

Vero Biotech Inc.

Geno LLC

Lewis J Rubin

Thomas Schmehl

Werner Seeger

Robert Voswinckel

Horst Olschewski

Robert Roscigno

Carl Sterritt

Martine A Rothblatt

David H Fine

Robert Frank Roscigno

Carmelle Remillard

Ying Yu

Jason X-j Yuan

Tammy Watts

Robert F Roscigno

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Treprostinil administration by inhalation

A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.

Method of determining vasoreactivity using inhaled nitric oxide

One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.

Treatment for pulmonary hypertension

The present invention relates to compositions related to a polynucleotide encoding a transient receptor potential channel gene. Also disclosed is the use of this polynucleotide, its homologs, fragments, variants and its resultant polypeptides in the diagnosis, prevention and treatment of disease, particularly idiopathic pulmonary arterial hypertension (IPAH). This invention also teaches the use of these polynucleotides and polypeptides as assays for drug discovery and therapies.

Regulating expression of transient receptor potential channel genes

Growing community of inventors

La Jolla, CA, United States of America

Lewis J Rubin